Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.75 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | CA4 | P22748 | 4/20 | 0.59 |
| ▸ | CA9 | Q16790 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804193 | 0.84 | CNR2 (0.85) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL6803486 | 0.79 | TP53 (0.47) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL6797972 | 0.79 | CNR2 (0.79) | CNR2TAS2R14CNR1POLBMEN1 | |
| SCHEMBL6802688 | 0.77 | CNR2 (0.75) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL1615931 | 0.75 | TAS2R14 (1.00) | TAS2R14POLBMEN1KMT2A | |
| SCHEMBL1278914 | 0.75 | TAS2R14 (1.00) | TAS2R14POLBMEN1KMT2A | |
| SCHEMBL9594878 | 0.75 | CNR2 (0.72) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL20387915 | 0.74 | CNR2 (0.70) | CNR2TAS2R14CNR1 | |
| SCHEMBL7814402 | 0.73 | CNR2 (0.72) | CNR2TAS2R14CNR1POLBMEN1 | |
| SCHEMBL30016802 | 0.73 | CNR2 (0.72) | CNR2TAS2R14CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | claimed |
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | CNR2 4684/4885TAS2R14 3019/4885CA12 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.